This regulatory path has recently been extended to murine in vivo pathology during viral infection (91) or graft-versus-host disease (92) and may affect the function of IL-22 not only under conditions of overt IFN production but likewise in the context of typ I IFN immunotherapy (90). The gene discussed is IFNA1; the disease is graft versus host disease.